Non-Muscle Invasive Bladder Carcinoma — Trials

Non-Muscle Invasive Bladder Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 55
Recruiting: 35
Ph III recruiting: 8
Growth YoY: —
Industry share: 36%
Top sponsor: Janssen Research & Development, LLC
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–13 of 13 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06770582	Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial	recruiting	Phase 2	160	National Cancer Institute (NCI)NIH	2	Sep 28, 2026	clinicaltrials
NCT06833073	A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)	recruiting	Phase 2	308	Merck Sharp & Dohme LLCINDUSTRY	19	Sep 28, 2026